U.S. markets closed

Astellas Pharma Inc. (YPH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
14.40-0.14 (-0.96%)
At close: 04:27PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.54
Bid14.36 x 80000
Ask14.61 x 70000
Day's Range14.40 - 14.59
52 Week Range13.15 - 15.62
Avg. Volume166
Market Cap26.507B
Beta (5Y Monthly)0.55
PE Ratio (TTM)25.26
Earnings DateN/A
Forward Dividend & Yield0.44 (3.02%)
Ex-Dividend DateMar 30, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for YPH.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • American City Business Journals

      Dallas-based Taysha Gene Therapies to receive $50M investment from Japanese pharmaceutical company

      The investment will go towards Taysha's adeno-associated virus gene therapy development programs for the treatment of Rett syndrome and giant axonal neuropathy.

    • Benzinga

      Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs

      Japan-based Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) announced a strategic investment to support the advancement of Taysha Gene Therapies Inc's (NASDAQ: TSHA) adeno-associated virus (AAV) gene therapy development programs for of Rett syndrome and Giant Axonal Neuropathy (GAN). In March this year, Taysha slashed 35% of its workforce and narrowed its R&D focus to extend its cash runway to Q4 of 2023. It also narrowed its focus to registration-directed gene therapy programs in GAN and Rett syn

    • Benzinga

      Astellas' Menopause Drug Under FDA Review

      The FDA accepted Astellas Pharma Inc's (OTC: ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in a phase 3 trial conducted in Asia. With the FDA's acceptance of Astellas' marketing application for fezolinetant, the company expects a regulatory decision by February 22, 2023, following the use of a priority review voucher. The application is based on the results from the BRIGHT SKY program, which included three Phase 3 clinical trials that collectively enrolle